Biomarker analysis reported higher levels of neuroinflammation and lower levels of neurotrophin in AYAC, suggesting that AYA patients newly diagnosed with cancer are at high risks of developing CRCI even prior to the receipt of systemic treatment. Here, BDNF is linked to cancer.